[1] T. Bieber, “Atopic dermatitis,” N. Engl. J. Med., vol. 358, no. 14, pp. 1483–1494, Apr. 2008, doi: 10.1056/NEJMra074081.
[2] P. E. Martin et al., “Which infants with eczema are at risk of food allergy? Results from a population-based cohort,” Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., vol. 45, no. 1, pp. 255–264, Jan. 2015, doi: 10.1111/cea.12406.
[3] N. Ravnborg et al., “Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis,” J. Am. Acad. Dermatol., vol. 84, no. 2, pp. 471–478, Feb. 2021, doi: 10.1016/j.jaad.2020.02.055.
[4] A. E. van der Hulst, H. Klip, and P. L. P. Brand, “Risk of developing asthma in young children with atopic eczema: a systematic review,” J. Allergy Clin. Immunol., vol. 120, no. 3, pp. 565–569, Sep. 2007, doi: 10.1016/j.jaci.2007.05.042.
[5] J. M. Biagini Myers and G. K. Khurana Hershey, “Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies,” J. Pediatr., vol. 157, no. 5, pp. 704–714, Nov. 2010, doi: 10.1016/j.jpeds.2010.07.009.
[6] “Skin Care Tips for Atopic Dermatitis (Eczema) | AAAAI.” Accessed: Jan. 05, 2024.
[7] M. J. Cork et al., “Epidermal barrier dysfunction in atopic dermatitis,” J. Invest. Dermatol., vol. 129, no. 8, pp. 1892–1908, Aug. 2009, doi: 10.1038/jid.2009.133.
[8] C. M. Olesen et al., “Altered Maturation of the Skin Microbiome in Infants with Atopic Dermatitis,” Acta Derm. Venereol., vol. 102, p. adv00817, Nov. 2022, doi: 10.2340/actadv.v102.2275.
[9] I. R. Serghiou, M. A. Webber, and L. J. Hall, “An update on the current understanding of the infant skin microbiome and research challenges,” Curr. Opin. Microbiol., vol. 75, p. 102364, Oct. 2023, doi: 10.1016/j.mib.2023.102364.
[10] A. Y.-K. Thye et al., “Gut-Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis,” Biomedicines, vol. 10, no. 5, p. 1037, Apr. 2022, doi: 10.3390/biomedicines10051037.
[11] M. R. Mahmud et al., “Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases,” Gut Microbes, vol. 14, no. 1, p. 2096995, 2022, doi: 10.1080/19490976.2022.2096995.
[12] S. Sinha, G. Lin, and K. Ferenczi, “The skin microbiome and the gut-skin axis,” Clin. Dermatol., vol. 39, no. 5, pp. 829–839, 2021, doi: 10.1016/j.clindermatol.2021.08.021.
[13] B. De Pessemier, L. Grine, M. Debaere, A. Maes, B. Paetzold, and C. Callewaert, “Gut-Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions,” Microorganisms, vol. 9, no. 2, p. 353, Feb. 2021, doi: 10.3390/microorganisms9020353.
[14] I. Salem, A. Ramser, N. Isham, and M. A. Ghannoum, “The Gut Microbiome as a Major Regulator of the Gut-Skin Axis,” Front. Microbiol., vol. 9, p. 1459, 2018, doi: 10.3389/fmicb.2018.01459.
[15] R. Katta and M. Schlichte, “Diet and Dermatitis: Food Triggers,” J. Clin. Aesthetic Dermatol., vol. 7, no. 3, pp. 30–36, Mar. 2014.
[16] T. Werfel et al., “Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN,” Allergy, vol. 62, no. 7, pp. 723–728, Jul. 2007, doi: 10.1111/j.1398-9995.2007.01429.x.
[17] M. Vancamelbeke and S. Vermeire, “The intestinal barrier: a fundamental role in health and disease,” Expert Rev. Gastroenterol. Hepatol., vol. 11, no. 9, pp. 821–834, Sep. 2017, doi: 10.1080/17474124.2017.1343143.
[18] M. Niewiem and U. Grzybowska-Chlebowczyk, “Intestinal Barrier Permeability in Allergic Diseases,” Nutrients, vol. 14, no. 9, p. 1893, Apr. 2022, doi: 10.3390/nu14091893.
[19] P. A. Nieto et al., “Improving immune-related health outcomes post-cesarean birth with a gut microbiome-based program: A randomized controlled trial,” Pediatric Allergy and Immunology, vol. 36, no. 9, p. e70182, 2025, doi: 10.1111/pai.70182.
[20] M. Derrien, E. E. Vaughan, C. M. Plugge, and W. M. de Vos, “Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium,” Int. J. Syst. Evol. Microbiol., vol. 54, no. Pt 5, pp. 1469–1476, Sep. 2004, doi: 10.1099/ijs.0.02873-0.
[21] S. Y. Geerlings, I. Kostopoulos, W. M. de Vos, and C. Belzer, “Akkermansia muciniphila in the Human Gastrointestinal Tract: When, Where, and How?,” Microorganisms, vol. 6, no. 3, p. 75, Jul. 2018, doi: 10.3390/microorganisms6030075.
[22] Q. Zhou et al., “Gut bacteria Akkermansia is associated with reduced risk of obesity: evidence from the American Gut Project,” Nutr. Metab., vol. 17, p. 90, 2020, doi: 10.1186/s12986-020-00516-1.
[23] Q. Zhou et al., “Association Between Gut Akkermansia and Metabolic Syndrome is Dose-Dependent and Affected by Microbial Interactions: A Cross-Sectional Study,” Diabetes Metab. Syndr. Obes. Targets Ther., vol. 14, pp. 2177–2188, 2021, doi: 10.2147/DMSO.S311388.
[24] M. C. Dao et al., “Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology,” Gut, vol. 65, no. 3, pp. 426–436, Mar. 2016, doi: 10.1136/gutjnl-2014-308778.
[25] G. Galazzo et al., “Development of the Microbiota and Associations With Birth Mode, Diet, and Atopic Disorders in a Longitudinal Analysis of Stool Samples, Collected From Infancy Through Early Childhood,” Gastroenterology, vol. 158, no. 6, Art. no. 6, May 2020, doi: 10.1053/j.gastro.2020.01.024.
[26] Y. M. Park et al., “Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant,” Allergy Asthma Immunol. Res., vol. 12, no. 2, pp. 322–337, Mar. 2020, doi: 10.4168/aair.2020.12.2.322.
[27] L. D. H. Ta et al., “A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema,” Gut Microbes, vol. 12, no. 1, Art. no. 1, Mar. 2020, doi: 10.1080/19490976.2020.1801964.
[28] H. Liu et al., “Butyrate: A Double-Edged Sword for Health?,” Adv. Nutr. Bethesda Md, vol. 9, no. 1, pp. 21–29, Jan. 2018, doi: 10.1093/advances/nmx009.
[29] M. Gurung et al., “Role of gut microbiota in type 2 diabetes pathophysiology,” EBioMedicine, vol. 51, p. 102590, Jan. 2020, doi: 10.1016/j.ebiom.2019.11.051.
[30] I. O’Neill, Z. Schofield, and L. J. Hall, “Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases,” Emerg. Top. Life Sci., vol. 1, no. 4, pp. 333–349, Nov. 2017, doi: 10.1042/ETLS20170058.
[31] M. Kalliomäki, S. Salminen, H. Arvilommi, P. Kero, P. Koskinen, and E. Isolauri, “Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial,” Lancet Lond. Engl., vol. 357, no. 9262, Art. no. 9262, Apr. 2001, doi: 10.1016/S0140-6736(00)04259-8.
[32] M. Nermes, J. M. Kantele, T. J. Atosuo, S. Salminen, and E. Isolauri, “Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis,” Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., vol. 41, no. 3, pp. 370–377, Mar. 2011, doi: 10.1111/j.1365-2222.2010.03657.x.